Clinical trial
A Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Tolerability (Part A), and Efficacy (Part B), of ORJ-001 in Patients With Idiopathic Pulmonary Fibrosis (ORBIT-IPF)
NCT07869147 is registered in ClinicalTrials.gov with Oorja Bio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Tolerability (Part A), and Efficacy (Part B), of ORJ-001 in Patients With Idiopathic Pulmonary Fibrosis (ORBIT-IPF)
- Lead sponsor
- Oorja Bio, Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- October 31, 2026
- Completion date
- March 31, 2029
- Enrollment
- 95 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.